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CeRecent advances in unrelated cord blood transplantation (UCBT) and high-resolution typing of human
leukocyte antigen (HLA) from an unrelated donor have increased choices in alternative donor/stem cell
source selection. We assessed HLA-mismatched locus-specific comparison of the outcomes of 351 single-
unit UCB and 1,028 unrelated bone marrow (UBM) adult recipients 16 years old or older at the time of
transplantation who received first stem cell transplantation with myeloablative conditioning for acute
leukemia or myelodysplastic syndromes. With adjusted analyses, HLA 0 to 2 mismatched UCBT showed
similar overall mortality (relative risk [RR] 5 0.85, 95% confidence interval [CI], 0.68-1.06; P 5 .149)
compared with that of single-HLA-DRB1-mismatched UBMT. UCBT showed inferior neutrophil recovery
(RR 5 0.50, 95% CI, 0.42-0.60; P\ .001), lower risk of acute graft-versus-host disease (RR 5 0.55, 95%
CI, 0.42-0.72; P\ .001), and lower risk of transplantation-related mortality (RR 5 0.68, 95% CI, 0.50-
0.92; P5.011) compared with single-HLA-DRB1-mismatched UBMT. No significant difference was observed
for risk of relapse (RR5 1.28, 95%CI, 0.93-1.76; P5.125). HLA 0 to 2 antigen-mismatchedUCBT is a reason-
able second alternative donor/stem cell source with a survival outcome similar to that of single-HLA-DRB1-
mismatched or other 7 of 8 UBMT.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is a widely used, curative treatment for hema-
tologic malignancies. When available, a human leuko-
cyte antigen (HLA)-identical sibling is the donor of
choice. However, only about 30% of candidates eligi-
ble for allogeneic HSCT will have such a donor. In
addition, older patients with older siblings have more
difficulty finding such a donor capable of stem cell
donation. High-resolution donor-recipient HLA
matching has contributed to the success of unrelated
donor marrow transplantation, and the current first
recommended alternative donor after an HLA-
matched sibling for HSCT is an HLA-A, -B, -C,
and -DRB1 8 of 8-allele-matched unrelated donor
[1-4]. However, there are still a significant number of
patients for which finding an HLA 8 of 8-matched
unrelated donor is difficult and for whom a second
alternative donor/stem cell source should be found.
The effect of HLA mismatches after bone marrow
transplantation from unrelated donors (UBMT) has
been well studied, and single mismatched UBM
donors are usually selected as a second alternative
donor/stem cell source [1-4]. Lee al. [3] showed that
a single mismatch, antigen-level, or high-resolution,
at HLA-A, -B, -C, or -DRB1 loci was associated
with higher mortality and decreased survival. How-
ever, the reduction in survival may be acceptable in
comparison with the survival rates for currently avail-
able alternative treatments. Analyses from the Japan
Marrow Donor Program (JMDP) showed better
survival in HLA class II mismatched recipients; thus,
single-DRB1-mismatched UBM donor is currently
a second alternative in Japan [1,2,5].
Recent advances in unrelated cord blood transplan-
tation (UCBT) have provided patients with increased
choices for a second alternative donor/stem cell source
[6].Clinical comparison studiesof cordblood transplan-
tation andHLA-A, -B, and -DRB1 6 of 6 allele-matched
bone marrow transplantation for leukemia from unre-
lated donors in adult recipients showed comparable
results [7-9]. More recently, promising outcomes of
UCBT were shown compared with HLA-A, -B, -C,
and -DRB1 8 of 8 allele-matched UBMT, the current
first alternative donor/stem cell source [10-12].
The aim of this study was to determine the utility
of UCBT as a second-alternative donor source in adult
patients with acute leukemia or myelodysplastic
syndromes. It is common today to perform high-
resolution typing of HLA for donor selection of
unrelated donors; thus, we performed mismatched-
allele-specific analyses for comparison of HLA-
mismatched UBMT and UCBT in terms of overall
survival (OS) and other HSCT outcomes, setting
single-DRB1-mismatched UBMT, the current second
alternative, as the reference.PATIENTS AND METHODS
Collection of Data and Data Source
The recipients’ clinical data were provided by the
Japan Cord Blood Bank Network (JCBBN) and the
JMDP [13]. Peripheral blood stem cell donation
from unrelated donors was not permitted in Japan
during the study period. All 11 cord blood banks in
Japan are affiliated with JCBBN. Both JCBBN and
JMDP collect recipients’ clinical information at 100
days posttransplantation. Patients’ information on sur-
vival, disease status, and long-term complications
including chronic graft-versus-host (cGVHD) disease
and second malignancies is renewed annually using
follow-up forms. This study was approved by the insti-
tutional review board of Nagoya University Graduate
School of Medicine.Patients
The subjects were adult patients of at least 16 years
of age with acute myeloid leukemia, acute lymphoblas-
tic leukemia, and myelodysplastic syndromes, who
were recipients of first UBMT or UCBTwith myeloa-
blative conditioning. All patients in the UCBT cohort
received a single-unit CB. Transplantation years were
between 1996 and 2005 for UBMT and between 2000
and 2005 for UCBT to avoid the first 3 years of a pio-
neering period (1993-1995 for UBMT and 1997-1999
for UCBT). There were no statistically significant
differences between UBMT in 1996-1999 and
UBMT in 2000-2005 in probabilities of OS (41% ver-
sus 44%, at 3 years posttransplantation; P5 .86) and in
relapse-free survival (RFS) (40% versus 40%, at 3 years
posttransplantation; P 5 .93).
Among 2,253 UBMT recipients with complete
HLA high-resolution data, the following recipients
with HLA -A, -B, -C, and -DRB1 8 of 8 allele match
(n 5 1,079) and more than three mismatches (5 of 8
allele match [n 5 117], 4 of 8 allele match [n 5 24],
3 of 8 allele match [n 5 4], 2 of 8 allele match [n 5
1]) were excluded. There were no statistically signifi-
cant differences in risk of mortality or treatment failure
(RFS) associated with single high-resolution (allele)
versus single low-resolution (antigen) mismatches
(data not shown), so in the analyses, allele and antigen
mismatches were considered equivalent. HLA match-
ing of cord blood was performed using low-resolution
molecular typing methods for HLA-A and -B, and
high-resolution molecular typing for HLA-DRB1.
Of 557 recipients of CB with complete HLA data,
105 recipients with three mismatches and nine recipi-
ents with four mismatches were excluded. A total of
1,028 UBMT recipients (248 HLA class II locus mis-
matched, 424 HLA class I locus mismatched, and 356
HLA 2 loci mismatched) and 351UCBT recipients (20
HLA-A, -B, low-resolution and -DRB1 matched, 87
782 Biol Blood Marrow Transplant 18:780-787, 2012Y. Atsuta et al.locus mismatched, and 244 2 loci mismatched) were
the subjects for analyses. Both host-versus-graft and
graft-versus-host directions were accounted for in
terms of HLA mismatch.
HLATyping
Alleles at the HLA-A, -B, -C, and -DRB1 with
unrelated bone marrow donor-recipient pairs and
for HLA-DRB1 for unrelated cord blood donor-
recipient pairs were identified by the methods
described previously [1,5,14]. Serologic or antigen-
level typing was performed with a standard two-stage
complement-dependent test of microcytotoxicity or
low-resolution DNA-based typing usually by collaps-
ing the four-digit typing result back to its first two
digits in part.
Definitions
The primary outcome of the analyses was OS,
defined as time from transplantation to death from
any cause. A number of secondary endpoints were
also analyzed. Neutrophil recovery was defined by an
absolute neutrophil count of at least 500 cells per cubic
millimeter for three consecutive points; platelet recov-
ery was defined by a count of at least 50,000 platelets
per cubic millimeter without transfusion support. Di-
agnosis and clinical grading of acute GVHD
(aGVHD) were performed according to the estab-
lished criteria [15,16]. Relapse was defined as
a recurrence of underlying hematologic malignant
diseases. Transplantation-related death was defined
as death during a continuous remission. RFS was
defined as survival in a state of continuous remission.
Statistical Analysis
Descriptive statistical analysis was performed to
assess patient baseline characteristics, diagnosis,
disease status at conditioning, donor-patient ABO
mismatches, preparative regimen, and GVHD
prophylaxis. Medians and ranges are provided for
continuous variables and percentages for categoric
variables. Cumulative incidence curves were used in
a competing-risks setting to calculate the probability of
aGVHD and cGHVD, relapse, and transplantation-
related mortality (TRM) [17]. Gray’s test was used
for group comparison of cumulative incidences [18].
Adjusted comparison of the groups on OS and RFS
was performed with the use of the Cox proportional-
hazards regression model [19]. For other outcomes
with competing risks, Fine and Gray’s proportional-
hazards model for subdistribution of a competing
risk was used [20]. For neutrophil and platelet recov-
ery, death before neutrophil or platelet recovery was
the competing event; for GVHD, death without
GVHD and relapse were the competing events; for
relapse, death without relapse was the competingevent; and, for TRM, relapse was the competing event
[21]. Adjusted probabilities of OS and RFS were
estimated using the Cox proportional-hazards regres-
sion model, with consideration of other significant
clinical variables in the final multivariate models.
The variables considered were the patient’s age at
transplantation, patient’s sex, donor-patient sex mis-
match, donor-patient ABO mismatch, diagnosis,
disease status at conditioning, the conditioning regi-
men, and the type of prophylaxis against GVHD. Fac-
tors differing in distribution between CB and BM
recipients and factors known to influence outcomes
were included in the final models. Variables with
more than two categories were dichotomized for the fi-
nal multivariate model. Variables were dichotomized
as follows: patient age .40 or\40 years at transplan-
tation, recipient’s sex, sex-mismatched donor-patient
pair versus sex-matched pair, donor-recipient ABO
major mismatch versus others for ABO matching, ad-
vanced versus standard (first and second complete
remission of acute myeloid leukemia, first complete
remission of acute lymphoblastic leukemia, or refrac-
tory anemia or refractory anemia with ring sidoblasts
of myelodysplastic syndromes) risk of the disease,
cyclophosphamide, and total-body irradiation (TBI)
or busulfan and cyclophosphamide or others for
conditioning regimen, and cyclosporine-based versus
tacrolimus-based prophylaxis against GVHD. No sig-
nificant interactions were identified between each
variable and HLA disparity/stem cell source groups.
All P values were two-sided.RESULTS
Patient Characteristics
Table 1 shows characteristics of patients, their
disease, and transplantation regimens. Proportions of
females, sex-mismatched donor-recipient pairs, and
ABO mismatched donor recipient pairs were larger
in cord blood recipients (P \ .001, P \ .001, and
P \ .001, respectively). UCB recipients were older
than recipients of UBM (median age, 37 years versus
34 years; P\ .001). A preparative regimen with TBI
and cyclophosphamide was used in the majority of
patients in all groups, and cytosine arabinoside was
supplemented for CB recipients in addition to TBI
and cyclophosphamide in about half the recipients
with cyclophosphamide and TBI. For GVHD
prophylaxis, tacrolimus and short-term methotrexate
was used preferentially in BM recipients (61% of
DRB1-one-mismatched BM recipients), while cyclo-
sporine A and short-term methotrexate was used
preferentially in CB recipients (61%). The median
follow-up period for survivors was 2.1 years (range,
0.1-6.2) for CB recipients and 5.5 (range, 0.3-11.6)
years for BM recipients.
Table 1. Patient, Disease, and Transplantation Characteristics According to Stem Cell Source and Number of Mismatched Loci
Bone Marrow Transplant
Cord Blood
Transplantation
Class II One Locus
Mismatch
Class I One Locus
Mismatch
Two Loci
Mismatch
N (%) N (%) N (%) N (%)
Number of transplantations 248 424 356 351
Patient age at transplantation
Median (range) 36 (16-60) 34 (16-67) 34 (16-59) 37 (16-58)
Patient sex
Male 151 (61) 241 (57) 210 (59) 162 (46)
Female 97 (39) 183 (43) 146 (41) 189 (54)
Sex matching
Matched 145 (58) 268 (63) 217 (61) 170 (48)
Male to female 52 (21) 82 (19) 73 (21) 97 (28)
Female to male 50 (20) 71 (17) 64 (18) 84 (24)
Unknown 1 (<1) 3 (1) 2 (1) 0 (0)
Diagnosis
AML 135 (54) 204 (48) 172 (48) 193 (55)
ALL 78 (31) 149 (35) 135 (38) 113 (32)
MDS 35 (14) 71 (17) 49 (14) 45 (13)
Disease status
Standard 124 (50) 214 (50) 168 (47) 147 (42)
Advanced 114 (46) 195 (46) 169 (47) 174 (50)
Unknown 10 (4) 15 (4) 19 (5) 30 (9)
ABO matching
Matched 119 (48) 184 (43) 153 (43) 114 (32)
Minor mismatch 53 (21) 108 (25) 85 (24) 99 (28)
Major mismatch 67 (27) 116 (27) 97 (27) 73 (21)
Bidirectional 8 (3) 12 (3) 14 (4) 64 (18)
Unknown 1 (<1) 4 (1) 7 (2) 1 (<1)
HLA-mismatched number and direction
Matched 20 (6)
One locus mismatched 87 (25)
HVG direction 16 (6) 38 (9) 8 (9)
GVH direction 17 (7) 30 (7) 8 (9)
Both directions 215 (87) 356 (84) 71 (82)
Two loci mismatched 244 (70)
Two HVG direction 4 (1) 2 (1)
One HVG direction and one GVH direction 6 (2) 4 (2)
Two GVH direction 4 (1) 3 (1)
One both directions and one HVG direction 42 (12) 40 (16)
One both directions and one GVH direction 29 (8) 28 (11)
Two both directions 271 (76) 167 (68)
No. of nucleated cells infused (107/kg)
Median 25.0 24.5 23 2.46
Range 2.40-59.8 2.10-97.5 1.5-66.0 1.41-6.01
Preparative regimen
CY + TBI 94 (38) 168 (40) 151 (42) 109 (31)
CY + CA + TBI 46 (19) 78 (18) 74 (21) 124 (35)
CY + BU + TBI 20 (8) 39 (9) 27 (8) 15 (4)
Other TBI regimen 45 (18) 70 (17) 61 (17) 80 (23)
BU + CY 34 (14) 54 (13) 30 (8) 21 (6)
Other non-TBI regimen 9 (4) 15 (4) 13 (4) 2 (1)
GVHD prophylaxisis
Cycrosporine A + sMTX 87 (35) 221 (52) 150 (42) 213 (61)
Cyclosporine A ± other 1 (<1) 5 (1) 5 (1) 24 (7)
Tacrolimus + sMTX 152 (61) 191 (45) 193 (54) 76 (22)
Tacrolimus ± other 8 (3) 5 (1) 6 (2) 35 (10)
Others 0 (0) 2 (<1) 2 (<1) 3 (1)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BU, oral busulfan; CA, citarabine; CY, cyclophosphamide; GVH,
graft-versus-host; HVG, host-versus-graft; MDS, myelodysplastic syndomes; sMTX, short-term methotrexate.
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OS and RFS
OS and RFS for CB recipients were similar
when compared with that of single-HLA-DRB1-
mismatched BM recipients (relative risk [RR] 5 0.85,
95% confidence interval [CI], 0.68-1.06; P 5 .149
for OS and RR 5 0.97, 95% CI, 0.92-1.35;
P 5 .747) (Table 2).
The adjusted probabilities of survival at 3 years
posttransplantation of CB recipients (47%) were notdifferent from those of singleHLA-DRB1mismatched
BM recipients (41%; P 5 .19) or single HLA class
I-mismatched BM recipients (47%; P 5 .96), but
superior to those of 6 of 8 BM recipients
(38%; P 5 .014) (Figure 1A). Figure 1B shows ad-
justed RFS curves (42% for CB recipients, 36%
for single HLA-DRB1-mismatched BM, 44% for
single HLA class I-mismatched BM, and 36% for
6 of 8 BM recipients, at 3 years posttransplant)
(P values of comparison between CB and single
HLA-DRB1-mismatched BM, CB, and single HLA
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cipients were 0.80, 0.12, and 0.43, respectively).
Relapse and TRM
There was no significant increase of relapse
rates among CB recipients when compared with
DRB1 single-mismatched BM recipients (RR 5 1.28,
95% CI, 0.93-1.76; P 5 .125). The risk of TRM was
lower in CB recipients compared with that of single
HLA-DRB1-mismatched BM recipients (RR 5 0.68,
95% CI, 0.50-0.92; P 5 .011) (Table 2). The risk of
TRM was also lower in CB recipients when compared
with 6 of 8 BM recipients (RR 5 0.52, 95% CI,
0.39-0.68; P\ .001).
Hematologic recovery
Neutrophil and platelet recovery was inferior in
CB recipients, as shown in Table 3 (RR 5 0.50, 95%
CI, 0.42-0.60; P \ .001 for neutrophil recovery,
RR 5 0.52, 95% CI, 0.42-0.63; P\ .001 for platelet
recovery).
Acute GVHD and chronic GVHD
The risk of grade 2 to 4 or severe (grades 3-4)
aGVHD was lower in CB recipients than that of single
HLA-DRB1-mismatched BM recipients (RR 5 0.55,
95% CI, 0.42-0.72; P\ .001 for grade 2 to 4 aGVHD
and RR5 0.43, 95%CI, 0.27-0.58; P\ .001 for severe
aGVHD) (Table 4). Unadjusted cumulative incidence
of severe aGVHD was 9% for CB, 19% for single
HLA-DRB1-mismatched BM, 18% for single HLAFigure 1. Adjusted probabilities of OS (A) and RFS (B). The adjusted 3-
year probabilities of OS for unrelated cord blood recipients, single-HLA-
DRB1-mismatched unrelated bone marrow (UBM) recipients, single-
HLA-class-I-mismatched UBM, and 6 of 8 UBM recipients were 47%,
41%, 47%, and 38%, respectively (A). The adjusted 3-year probabilities
of RFS were 42%, 36%, 44%, and 36%, respectively (B).
Table 3. Multivariate Analyses of Neutrophil and Platelet Recovery
Degree of HLA Mismatch N
Neutrophil Recovery Platelet Recovery
RR (95% CI) P value RR (95% CI) P value
Bone marrow transplantation Single DRB1 (7/8) 248 1.00 1.00
Single A or B (7/8) 137 1.31 (1.04-1.65) .021 1.31 (1.01-1.70) .039
Single C (7/8) 287 1.19 (0.98-1.43) .069 0.98 (0.79-1.21) .840
C + DRB1 (6/8) 144 0.96 (0.77-1.20) .735 0.79 (0.62-1.02) .065
A/B + C (6/8) 122 1.14 (0.89-1.45) .307 0.84 (0.63-1.13) .255
Other two loci (6/8) 90 0.89 (0.68-1.14) .346 0.80 (0.58-1.10) .174
Cord blood transplantation 351 0.50 (0.42-0.60) <.001 0.52 (0.42-0.63) <.001
RR indicates relative risk; CI, confidence interval.
Adjusted by patient age at transplantation >40 versus <40, patient sex, donor-patient sexmismatch versusmatched, ABOmajormismatch versus others,
advanced versus standard disease status at transplant, cyclophosphamide, and total-body irradiation or busulfan and cyclophosphamide for conditioning
versus other conditioning regimen, and cyclosporine-based versus tacrolimus-based prophylaxis against graft-versus-host disease.
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days posttransplantation (P\ .001 between CB and
single HLA-DRB1-mismatched BM) (Figure 2A).
Among recipients who survived at least 100 days
posttransplantaton, the risk of developing cGVHD
and extensive-type cGVHD was not significantly
increased in all HLA disparity groups of CB recipients
when compared with that of HLA-DRB1-allele/anti-
gen-mismatched BM recipients (RR 5 1.36, 95% CI,
0.99-1.88; P 5 .057 for cGVHD, and RR 5 0.86,
95% CI, 0.55-1.34; P 5 .500 for extensive-type
cGVHD). The unadjusted cumulative incidence of
extensive-type cGVHD was 17% for CB recipients,
20% for single HLA-DRB1-mismatched BM, 25%
for single HLA class I-mismatched BM, and 30% for
6 of 8 BM recipients at year posttransplantation (P 5
.34 between CB and single HLA-DRB1-mismatched
BM) (Figure 2B).DISCUSSION
Our main objective was to compare OS after trans-
plantation of UCBT and single-HLA-mismatched
UBMT and to provide useful data for selection of an
appropriate donor and graft source in second stem
cell source/donor selection for adults with hematologic
malignancy. To the best of our knowledge, this is the
first study to involve mismatched allele/antigen-
specific analyses including CB for the process of donor
selection. Our results suggest that 0 to 2 HLA-
mismatched UCB is a reasonable second alternative
of choice for adult patients with leukemia, with similar
survival to that of single DRB1-mismatched or other 7
of 8UBM recipients, the current first choice for second
alternative donor/stem cells.
Neutrophil and platelet recovery was slower in CB
recipients than BM recipients, consistent with the re-
sults of previous reports [7-10,12]. This is the major
limitation of the use of UCB, and several strategies
have been studied to reduce the neutropenic period,
such as screening for patients’ pretransplantation
anti-HLA antibodies and their specificity, transplanta-
tion of 2 UCB units if a single UCB unit with an ade-quate cell dose is not available, or direct infusion of
UCB into bone marrow [22-26].
Despite higher HLA disparity at the antigen level
(69% 2 antigen mismatch, 25% antigen mismatch,
and 6% matched), UCB recipients showed lower
incidence of severe aGVHD than single DRB1-
mismatched UBM recipients, consistent with other
reports that compared UCB with single-mismatched
UBM (7 of 8) [8,11,12]. In our study, tacrolimus and
short-term methotrexate were used preferentially in
BM recipients, whereas cyclosporine A was used in
68% of CB recipients. Prior studies have shown
reduced severe aGVHD with tacrolimus, and this dif-
ference may have underscored the improved aGVHD
control of UCB over mismatched BM in unadjusted
analyses [27,28]. It is likely that decreased risk of
grade 2 to 4 aGVHD in UCB recipients contributed
to decreased risk of TRM among UCB recipients.
Increasing the number of HLAmismatches from 7
of 8 to 6 of 8 was associated with an approximately
10% reduction in survival in UBM recipients, which
was quite similar to the results from the National
Marrow Donor Program [3]. Because we eliminated
data from the first 3 pioneering years of unrelated
BMT, most of the bone marrow recipients and donors
were allele-typed for at least HLA-A, -B, and -DRB1
before transplantation. Survival outcomes of single
class I mismatch were not significantly different from
those of single class II mismatch in the current analy-
ses. We believe that allele typing of HLA-A, -B, and
-DRB1 before transplantation led to better selection
of the donor compared with that in the first several
years of UBMT. This study includes a large number
of fully typed BM and CB recipients, but there are
limitations. The choice of stem cell source is influ-
enced by many unmeasured factors that can affect
outcome. It is also influenced by the availability of ac-
ceptable HLA disparity for unrelated donors and
mainly cell dose for cord blood units. Although we
have adjusted for known risk factors and disparities
between groups, we cannot rule out the influence of
potential selection bias, which can only be excluded
in a randomized controlled trial. Transplantation years
Figure 2. Cumulative incidence of grade 3 to 4 aGVHD (A) and
extensive-type cGVHD (B). The cumulative incidences of grade 3 to 4
aGVHD at 100 days posttransplantation for unrelated cord blood recip-
ients, single HLA-DRB1-mismatched unrelated bone marrow (UBM)
recipients, and single HLA class I-mismatched UBM were 9%, 19%,
18%, and 22% (A). The cumulative incidences of extensive-type cGVHD
at 1-year posttransplantation were 17%, 20%, 25%, and 30% (B).
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786 Biol Blood Marrow Transplant 18:780-787, 2012Y. Atsuta et al.of UBM recipients included from 1996 and 1999, for
which there were no significant outcome differences
between UBMT performed in 1996 to 1999 and af-
ter 2000. In these periods, there were advances includ-
ing in supportive care and nutritional management,
introduction of new antifungal agents, and more fre-
quent use of tacrolimus, which may have affected
transplantation outcomes [27-32].
In conclusion, we suggest that 0 or 2 HLA-
mismatched UCB is a comparable second alternative
for adult patientswith leukemia in the absenceof thefirst
alternative, an8of 8UBMdonor,with survival similar to
that of single DRB1-mismatched or other 7 of 8 UBM
recipients. UCB may be preferred over single mis-
matched UBM when a transplantation is needed ur-
gently, considering the short time needed for UCBT.ACKNOWLEDGMENTS
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